Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Fuchs

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Plos One|November 30, 2011
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyLyubov Chaykovska, Karoline von Websky, Jan Rahnenführer, et al.
Translational Vision Science & Technology|May 17, 2022
Characterization and Validation of In Vitro and In Vivo Models to Investigate TNF-α-Induced Inflammation in Retinal DiseasesCarina M Weigelt, Nina Zippel, Holger Fuchs, et al.
Molecular Pharmaceutics|September 8, 2017
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp SubstratesClemens Braun, Atsushi Sakamoto, Holger Fuchs, et al.
Translational Vision Science & Technology|September 14, 2021
AAV-Mediated Expression of Human VEGF, TNF-α, and IL-6 Induces Retinal Pathology in MiceCarina M Weigelt, Holger Fuchs, Tanja Schönberger, et al.
Journal of Medicinal Chemistry|December 7, 2007
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetesMatthias Eckhardt, Elke Langkopf, Michael Mark, et al.
Cancer Chemotherapy and Pharmacology|June 8, 2014
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairmentDavid Schnell, Susanne Buschke, Holger Fuchs, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 4, 2019
The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in RodentsHolger Rosenbrock, Riccardo Giovannini, Gerhard Schänzle, et al.
Pharmaceutics|August 28, 2021
Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic RetinopathyCecile Lebon, Heike Neubauer, Marianne Berdugo, et al.
Scientific Reports|November 13, 2022
Transcriptome analysis of AAV-induced retinopathy models expressing human VEGF, TNF-α, and IL-6 in murine eyesKolja Becker, Carina M Weigelt, Holger Fuchs, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Plos One|November 30, 2011
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyLyubov Chaykovska, Karoline von Websky, Jan Rahnenführer, et al.
Translational Vision Science & Technology|May 17, 2022
Characterization and Validation of In Vitro and In Vivo Models to Investigate TNF-α-Induced Inflammation in Retinal DiseasesCarina M Weigelt, Nina Zippel, Holger Fuchs, et al.
Molecular Pharmaceutics|September 8, 2017
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp SubstratesClemens Braun, Atsushi Sakamoto, Holger Fuchs, et al.
Translational Vision Science & Technology|September 14, 2021
AAV-Mediated Expression of Human VEGF, TNF-α, and IL-6 Induces Retinal Pathology in MiceCarina M Weigelt, Holger Fuchs, Tanja Schönberger, et al.
Journal of Medicinal Chemistry|December 7, 2007
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetesMatthias Eckhardt, Elke Langkopf, Michael Mark, et al.
Cancer Chemotherapy and Pharmacology|June 8, 2014
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairmentDavid Schnell, Susanne Buschke, Holger Fuchs, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 4, 2019
The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in RodentsHolger Rosenbrock, Riccardo Giovannini, Gerhard Schänzle, et al.
Pharmaceutics|August 28, 2021
Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic RetinopathyCecile Lebon, Heike Neubauer, Marianne Berdugo, et al.
Scientific Reports|November 13, 2022
Transcriptome analysis of AAV-induced retinopathy models expressing human VEGF, TNF-α, and IL-6 in murine eyesKolja Becker, Carina M Weigelt, Holger Fuchs, et al.
Pageof 3